Association between dietary selenium intake and the prevalence of osteoporosis: a cross-sectional study

Wang, Yuqing; Xie, Dongxing; Li, Jiatian; Long, Huizhong; Wu, Jing; Wu, Ziying; He, Hongyi; Wang, Haochen; Yang, Tao; Wang, Yilun

doi:10.1186/s12891-019-2958-5

Cited by 37 publications

(42 citation statements)

References 59 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study showed a negative correlation between the amount of selenium intake and osteoporosis [ 122 ]. On the other hand, the serum selenoprotein level correlated positively with total BMD, and the serum selenium level with the total and femoral neck BMD in aging men from Europe.…”

Section: Microelements and Bone Mineral Density In Ibdmentioning

confidence: 99%

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

et al. 2020

View full text Add to dashboard Cite

The chronic character of inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, results in various complications. One of them is osteoporosis, manifested by low bone mineral density, which leads to an increased risk of fractures. The aetiology of low bone mineral density is multifactorial and includes both diet and nutritional status. Calcium and vitamin D are the most often discussed nutrients with regard to bone mineral density. Moreover, vitamins A, K, C, B12; folic acid; calcium; phosphorus; magnesium; sodium; zinc; copper; and selenium are also involved in the formation of bone mass. Patients suffering from inflammatory bowel diseases frequently consume inadequate amounts of the aforementioned minerals and vitamins or their absorption is disturbed, resulting innutritional deficiency and an increased risk of osteoporosis. Thus, nutritional guidelines for inflammatory bowel disease patients should comprise information concerning the prevention of osteoporosis.

show abstract

Section: Microelements and Bone Mineral Density In Ibdmentioning

confidence: 99%

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After reviewing the full-texts of the remaining 774 articles, 3 studies were excluded due to sample size smaller than 100, 2 studies were excluded due to repeated publications, 750 studies were excluded as diabetes mellitus was not investigated, and 5 studies were excluded because no information is given about BMD [ 28 – 32 ]. Finally, 14 relevant studies were included in this systematic review [ 33 – 46 ] (Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…These 14 case-controlled studies included 24,340 participants, and the sample size ranged from 255 to 6267. Five studies were conducted in China [ 33 , 34 , 39 , 44 , 46 ], two in Korea [ 43 , 45 ], two in Jordan [ 35 , 41 ], and the remaining in other countries. Most of the low bone density patients underwent dual-energy X-ray absorptiometry.…”

Section: Resultsmentioning

confidence: 99%

Is diabetes mellitus a risk factor for low bone density: a systematic review and meta-analysis

Qiu

Yang

et al. 2021

BMC Endocr Disord

View full text Add to dashboard Cite

Background This systematic review aimed to investigate whether diabetes mellitus is a risk factor for low bone density, as this might be important and necessary for doctors specialized in treating patients with low bone density. Methods PubMed, Embase, CINAHL, and SciELO were searched for cohort, case-control, and cross-sectional studies that investigated the effects of diabetes mellitus on bone mineral density till January 2020. Data screening and extraction are done independently, whereas the methodological quality of the studies was assessed according to the Newcastle-Ottawa Scale (NOS). Results A total of 14 studies that met the eligibility criteria including 24,340 participants were enrolled. The overall quality of the studies had a scale of over 6 points. The overall odds ratio (OR) regarding the risk of diabetes mellitus in low bone density patients was 1.20 [95% confidence interval (CI)0.80–1.79, P = 0.30], and type 2 diabetes mellitus (T2DM) (OR = 0.69 [0.11, 4.55], P = 0.70). Subgroup analysis revealed that whether females or males, developed or developing countries, T2DM, studies after 2015, and quality over 7 points (all P values > 0.05) showed no significant differences with the risk of low bone density, except type 1 diabetes mellitus (T1DM) (OR = 3.83 [1.64, 8.96], P = 0.002), and studies before 2015 (OR = 1.76 [1.06, 2.92], P = 0.03), and quality below 7 points (OR = 2.27 [1.50, 3.43], P = 0.0001). Funnel plot showed no significant asymmetry. Conclusions These findings revealed no relationship between T2DM and low bone density, and also, the evidence between T1DM and low bone density is inadequate, requiring further analysis of well-designed cohort studies.

show abstract

“…Higher selenium status is associated with BMD in men in the Netherlands. 22 Higher dietary selenium intake is associated with lower hip fracture risk in older adults in the USA 23 and higher BMD in middle-aged and older adults in China 46 and Europe. 14,22 However, there was no association with BMD in postmenopausal Turkish women.…”

Section: Resultsmentioning

confidence: 99%

Selenium supplementation to improve bone health in postmenopausal women: the SeMS three-arm RCT

et al. 2021

View full text Add to dashboard Cite

Background Observational and pre-clinical studies have reported an association between selenium status, bone density, bone turnover and fracture risk. Selenium is an anti-oxidant, so we hypothesised that selenium could reduce the pro-resorptive action of reactive oxygen species on osteoclasts. Population mortality data suggest that the optimum range for serum selenium is 120–150 µg/l. Most adults in Europe are relatively selenium insufficient compared with adults in the USA and other geographical areas. Objectives The objectives of the study were to determine if selenium supplementation in postmenopausal women with osteopenia decreased bone turnover, improved physical function or decreased markers of oxidative stress and inflammation. Design We conducted a 6-month double-blind, randomised, placebo-controlled trial. Setting This was a single-centre study in Sheffield, UK. Participants We recruited 120 postmenopausal women with osteopenia or osteoporosis. One hundred and fifteen women completed follow-up and were included in the intention-to-treat analysis. Interventions The interventions were sodium selenite as Selenase 200 µg/day, Selenase 50 µg/day (biosyn, Germany) and placebo. Main outcome measures The primary end point was urine N–terminal cross-linking telopeptide of type I collagen/Cr (NTX/Cr) at 26 weeks. Groups were compared with an analysis of covariance, through the use of Hochberg testing. Secondary end points were other biochemical markers of bone turnover, bone mineral density by dual-energy X-ray absorptiometry and physical function scores (short physical performance battery and grip strength). The mechanistic end points were markers of inflammation and anti-oxidant activity (glutathione peroxidase, highly sensitive C-reactive protein and interleukin 6). Results In the 200 µg/day group, mean serum selenium increased from 78.8 µg/l (95% confidence interval 73.5 to 84.2 µg/l) to 105.7 µg/l (95% confidence interval 99.5 to 111.9 µg/l) at 26 weeks. Urine NTX/Cr did not differ between treatment groups at 26 weeks. None of the secondary or mechanistic end-point measurements differed between the treatment groups at 26 weeks. Conclusions We conclude that selenium supplementation at these doses does not affect bone turnover (assessed by NTX/Cr) and is not beneficial for musculoskeletal health in postmenopausal women. Trial registration IRAS 200308, EudraCT 2016-002964-15 and ClinicalTrials.gov NCT02832648. Funding This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 6. See the NIHR Journals Library website for further project information.

show abstract

Association between dietary selenium intake and the prevalence of osteoporosis: a cross-sectional study

Cited by 37 publications

References 59 publications

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

Is diabetes mellitus a risk factor for low bone density: a systematic review and meta-analysis

Selenium supplementation to improve bone health in postmenopausal women: the SeMS three-arm RCT

Contact Info

Product

Resources

About